Last updated on March 2018

Safety and Efficacy of PD0332991 (Palbociclib) a Cyclin-dependent Kinase 4 and 6 Inhibitor in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Brief description of study

This multicenter, open-label, phase II trial aims to assess the safety and efficacy of palbociclib in adult patients with Oligodendroglioma or recurrent oligoastrocytoma anaplastic with the activity of the protein RB preserved.

Clinical Study Identifier: NCT02530320

Contact Investigators or Research Sites near you

Start Over

Elena Vicente

Hospital Insular de Canarias
Las Palmas de Gran Canaria, Spain
  Connect »

Jose Fuster

Hospital Son Espases
Palma de Mallorca, Spain
  Connect »

Estela Pineda

Hospital Cl nic de Barcelona
Barcelona, Spain
  Connect »

Miguel Gil Gil

ICO Hospitalet
Barcelona, Spain
  Connect »

Juan Manuel Sepúlveda

Hospital 12 de Octubre
Madrid, Spain
  Connect »

Mª Ángeles Vaz

Hospital Ram n y Cajal
Madrid, Spain
  Connect »

Begoña Pérez

Hospital Virgen del Rocio
Sevilla, Spain
  Connect »

Ángel Rodríguez

Hospital de Le n
León, Spain
  Connect »

Gema Duran

Hospital Regional de M laga
Málaga, Spain
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.